Erratum: Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
J Clin Oncol. 2024 Feb 1;42(4):486.
doi: 10.1200/JCO.23.02629.
Epub 2023 Dec 19.